Sangamo BioSciences | SGMO - Pre Tax Profit


Sangamo BioSciences reported $-36.05M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Alnylam Pharmaceuticals USD 177.81M 43.85M Jun/2026
Alterity Therapeutics Limited AUD -6.26M 1.52M Dec/2025
Amgen USD 2.08B 570M Mar/2026
Bayer EUR 321M 2.67B Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 647.3M 269.6M Jun/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Cipla INR 10.82B 3.33B Jun/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD -7.66M 64.51M Mar/2026
CSL USD 2.61B 1.21B Dec/2025
Gilead Sciences USD -7.53B 10.11B Jun/2026
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Grifols EUR 257.85M 190.87M Dec/2024
Ionis Pharmaceuticals USD -114M 21M Jun/2026
J&J USD 7.67B 988M Sep/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Novartis USD 4.27B 430M Jun/2026
Omeros USD -65.12M 21.27M Jun/2024
Pfizer USD -653M 5.84B Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR 837M 1.17B Jun/2026
Sarepta Therapeutics USD -1.75M 344.92M Jun/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Vertex Pharmaceuticals USD 1.39B 138.9M Jun/2026